for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zoetis Inc

ZTS.N

Latest Trade

117.29USD

Change

0.26(+0.22%)

Volume

107,909

Today's Range

116.67

 - 

118.02

52 Week Range

78.97

 - 

130.20

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
117.03
Open
116.67
Volume
107,909
3M AVG Volume
43.40
Today's High
118.02
Today's Low
116.67
52 Week High
130.20
52 Week Low
78.97
Shares Out (MIL)
477.56
Market Cap (MIL)
56,136.63
Forward P/E
32.81
Dividend (Yield %)
0.56

Next Event

Zoetis Inc at Credit Suisse Healthcare Conference - Scottsdale

Latest Developments

More

Zoetis Says CVMP Adopted By Consensus Positive Opinions For Renewal Of Marketing Authorisations For Coliprotec F4 And Zulvac SBV

Zoetis Q3 Adjusted Earnings Per Share $0.94

Zoetis Sets Quarterly Dividend Of $0.164 Per Share

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zoetis Inc

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.

Industry

Biotechnology & Drugs

Contact Info

10 Sylvan Way

+1.973.8227000

https://www.zoetis.com/

Executive Leadership

Michael B. McCallister

Non-Executive Independent Chairman of the Board

Juan Ramon Alaix

Chief Executive Officer, Director

Glenn David

Chief Financial Officer, Executive Vice President

Roxanne Lagano

Executive Vice President, Chief Human Resources Officer and Communications

Andrew Fenton

Executive Vice President and Chief Digital and Technology Officer

Key Stats

2.00 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

4.9K

2017

5.3K

2018

5.8K

2019(E)

6.2K
EPS (USD)

2016

1.960

2017

2.400

2018

3.130

2019(E)

3.592
Price To Earnings (TTM)
41.78
Price To Sales (TTM)
9.28
Price To Book (MRQ)
23.36
Price To Cash Flow (TTM)
32.15
Total Debt To Equity (MRQ)
267.36
LT Debt To Equity (MRQ)
267.36
Return on Investment (TTM)
15.57
Return on Equity (TTM)
13.94

Latest News

Latest News

Biotech is going to the dogs - and big profits await

For Jessica Lescault there is no question that her 6-year old English bulldog "Moose" deserves cutting-edge biotechnology cancer treatment as much as any human patient.

Factbox: Animal health sector aims to emulate Zoetis biotech leap

A commercial breakthrough in the field of complex therapeutic proteins for dogs by sector leader Zoetis <ZTS.N> has roused rivals to action in a hunt for biotechnology medicines to treat pets.

Factbox - Animal health sector aims to emulate Zoetis biotech leap

A commercial breakthrough in the field of complex therapeutic proteins for dogs by sector leader Zoetis <ZTS.N> has roused rivals to action in a hunt for biotechnology medicines to treat pets.

Zoetis to buy veterinary diagnostics firm Abaxis for $1.9 billion

Top animal health company Zoetis Inc <ZTS.N> will buy Abaxis Inc <ABAX.O> for $1.9 billion (£1.4 billion), looking to capture a bigger slice of the fast-growing market for diagnostics services that cater to household pets and farm animals.

BRIEF-Zoetis Says Upon Deal Termination By Abaxis Or Co, Termination Fee Of $70 Mln May Be Payable By Abaxis

* ZOETIS SAYS UPON DEAL TERMINATION BY ABAXIS OR CO, TERMINATION FEE OF $70 MILLION MAY BE PAYABLE BY ABAXIS - SEC FILING Source text: (https://bit.ly/2KprpqL) Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Zoetis To Acquire Abaxis for about $2 Bln In Aggregate

* ZOETIS TO ACQUIRE ABAXIS, A LEADING GLOBAL PROVIDER OF VETERINARY POINT-OF-CARE DIAGNOSTIC INSTRUMENTS

Zoetis to buy Abaxis for $1.9 bln in cash

Animal health company Zoetis Inc said on Wednesday it would buy Abaxis Inc, a maker of veterinary diagnostic instruments, for about $1.9 billion in cash.

BRIEF-Zoetis Announces Q1 Earnings Per Share $0.72

* Q1 EARNINGS PER SHARE VIEW $0.69 -- THOMSON REUTERS I/B/E/S

BRIEF-Zoetis Inc To Expand Animal Vaccine Research And Manufacturing In Suzhou, China

* ZOETIS INC SAYS TO EXPAND ANIMAL VACCINE RESEARCH AND MANUFACTURING IN SUZHOU, CHINA Source text for Eikon: Further company coverage:

BRIEF-Zoetis Says CEO Juan Alaix's 2017 Total Compensation Was $10.5 Mln Vs $9.5 Mln In 2016

* ZOETIS INC SAYS CEO JUAN RAMÓN ALAIX'S 2017 TOTAL COMPENSATION WAS $10.5 MILLION VERSUS $9.5 MILLION IN 2016 – SEC FILING Source text (https://bit.ly/2uJV1MK) Further company coverage:

BRIEF-Zoetis Inc Q4 Earnings Per Share $0.16

* ADJUSTED NET INCOME FOR 2017 EXCLUDES ONE-TIME PROVISIONAL NET TAX CHARGE OF $212 MILLION RELATED TO RECENTLY ENACTED TAX LEGISLATION IN U.S.

BRIEF-Zoetis Says Preliminarily Estimated Reduction To Gaap Net Income In Q4

* ZOETIS SAYS EVALUATING IMPACT OF U.S. TAX ACT, PRELIMINARILY ESTIMATED REDUCTION TO GAAP NET INCOME IN Q4 Source text: (http://bit.ly/2qDYvyf) Further company coverage:

BRIEF-Zoetis Launches Vanguard CIV H3N2/H3N8 Vaccine For Canine Influenza Virus

* ZOETIS LAUNCHES VANGUARD CIV H3N2/H3N8 VACCINE FOR CANINE INFLUENZA VIRUS Source text for Eikon: Further company coverage:

BRIEF-Zoetis Board Approves 20% Dividend Increase

* ZOETIS DECLARES FIRST QUARTER 2018 DIVIDEND; BOARD APPROVES 20% PAYMENT INCREASE

BRIEF-Zoetis Inc Q3 earnings per share $0.61

* Q3 earnings per share view $0.62 -- Thomson Reuters I/B/E/S

BRIEF-Zoetis announces pricing of $1.25 bln of senior notes

* Zoetis Inc - agreed to sell $1.25 billion of senior notes, consisting of $750 million aggregate principal amount of 3.000% senior notes due 2027

BRIEF-Immunovaccine announces achievement of milestones in collaboration with Zoetis to develop veterinary vaccines

* Immunovaccine announces achievement of milestones in collaboration with Zoetis to develop veterinary vaccines Source text for Eikon: Further company coverage:

BRIEF-Anatara and Zoetis to negotiate terms of an international Detach commercial agreement

* Anatara and Zoetis to negotiate terms of an international Detach® commercial agreement Source text for Eikon: Further company coverage:

BRIEF-Zoetis reports Q2 earnings per share $0.50

* Q2 earnings per share view $0.53 -- Thomson Reuters I/B/E/S

BRIEF-High Court of Ireland approves acquisition of Nexvet by Zoetis Inc's unit

* High Court of Ireland has approved acquisition of Nexvet by Zoetis Inc through its unit Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up